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Introduction
As men grow older circulating levels of testosterone (T) decline [1, 2] . Lower levels of T are associated with poorer health outcomes in older men including frailty, cardiovascular disease and mortality [3] [4] [5] . However, whether low T reflects existing ill-health or contributes to the development of disease remains unclear [5] . This debate has intensified following the report that in healthy, predominantly middle-aged men without major comorbidities, T levels might be stable and not show age-associated differences [6] . Similar T levels have also been reported when healthy young men were compared with healthy elderly men [7] . Therefore, lower T might reflect the presence of ill-health accumulated during ageing, representing a biomarker rather than a causal contributor to health outcomes. Alternatively, associations of lower T with poorer outcomes might be present in older men but attenuated in younger or middle-aged men.
In the circulation, T is present bound with high affinity to sex hormone-binding globulin (SHBG) and with lower affinity to albumin with a small proportion unbound or free. In large studies free T is commonly calculated rather than measured directly [8] . The increase in SHBG concentrations during ageing results in a greater reduction in calculated free compared to total T levels in older men [7, 9] . However biological significance of calculated free T and its utility in the prediction of health outcomes in ageing men is debated [10] . T is converted by 5α-reductase into dihydrotestosterone (DHT), a more potent ligand for the androgen receptor (AR), and by aromatase into estradiol (E2) a ligand for the estrogen receptor (ER)α or ERβ [11] . E2 levels have been associated with bone density in men [12] . Yet there are limited data comparing associations of T, DHT and E2 with physical, metabolic and other health-related factors in ageing men, which might clarify whether measuring levels of T Recently liquid chromatography-tandem mass spectrometry (LC-MS) has become established as the preferred methodology for assay of sex steroids, rather than immunoassays which exhibit loss of specificity and method-dependent bias [13] . We sought to test the hypothesis that T, DHT and E2 are differentially associated with physical, metabolic and other healthrelated factors in men spanning younger, middle and older ages by measuring these sex hormones using LC-MS in a large cohort of community-dwelling men.
Participants and Methods

Study population
Busselton is a coastal town in Western Australia, whose residents have participated in a series of health surveys from 1966 onwards. In 1994-1995, all surviving subjects of earlier Busselton surveys were invited to participate in a follow-up survey [14] . More than 90% of the Busselton population is of Caucasian ethnic origin. The present study is based on 2,143 men aged 17-97 years who attended the 1994/95 survey, who provided blood samples for analysis. The study was approved by the Human Research Ethics Committee of the University of Western Australia, and all participating men provided written informed consent.
Assessment of medical comorbidities
Methods used in the Busselton Health Survey have been described previously [14] . Men were asked to complete a comprehensive health and lifestyle questionnaire and underwent a physical assessment. Blood pressure was measured using a mercury sphygmomanometer after five minutes at rest in a sitting position. Height was measured using a stadiometer and weight in light underclothes. Smoking, diabetes, and the use of antihypertensive or glucoselowering medications were obtained via questionnaire. Medical history was assessed from questionnaire responses and also via the Western Australian Data Linkage System (WADLS), which captures electronically all admissions to public or private hospitals in Western Australia [15] . A history of cardiovascular disease (CVD), including coronary heart disease or stroke, was defined as any hospital admission with a primary or secondary diagnosis of CVD during the preceding 15 years prior to the survey. History of chronic obstructive pulmonary disease (COPD) and history of chronic renal disease (CRD) were similarly defined using hospital admissions history via WADLS. Metabolic syndrome scores were defined using the NCEP ATP III 2005 definition [16] . Hypertension was defined as systolic blood pressure ≥130 mmHg or diastolic blood pressure ≥85 mmHg or receipt of drug treatment for hypertension. Hyperglycemia was defined as fasting glucose ≥5.6 mmol/L.
Hypertriglyceridemia was defined as triglycerides ≥1.7 mmol/L or receipt of fibrates or nicotinic acid. Low high density lipoprotein (HDL) cholesterol was defined as HDL ≤1.0 mmol/L. Central obesity was defined as waist circumference ≥102 cm. The Metabolic Syndrome score was the number of these five risk components meeting the defined criteria and a participant was regarded as having the Metabolic Syndrome if three or more criteria were met.
Laboratory assays
Blood samples were collected in the early morning after an overnight fast. Collected serum was stored at -70 o C. Fasting serum cholesterol, HDL and triglycerides were determined at the time of the survey by standard enzymatic methods on a Hitachi 747 analyser (Roche Diagnostics, Australia). Glucose was measured using a hexokinase assay. Insulin was assayed 1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54  55  56  57  58  59  60   F  o  r  P  e  e  r  R  e  v  i  e  w   7 using a Tosoh A1A-600 immunoassay analyzer using a two-site immunoenzymometric assay.
The between-run coefficient of variation (CV) was 5.6% at 14.3 mU/L. We measured Creactive protein (CRP) using a particle-enhanced immunoturbidimetric assay on a Modular analyser (Roche Diagnostics, Germany). Inter-assay precision was 3.9% at 1.6 mg/L and 1.6% at 5 mg/L. Plasma adiponectin levels were measured by a commercially available quantitative sandwich enzyme immunoassay technique (R&D Systems Inc., Minneapolis, Minnesota, USA). The inter-assay coefficients of variation (CVs) ranged from 7.0 to 8.5%. Serum T, DHT and E2 were quantified within a single LC-MS run without derivatization using atmospheric pressure photo-ionisation in positive mode for androgens and negative mode for estrogens, from 200 µL samples as previously described [17] . Between run imprecision for T was 8.6% at a concentration of 5.3 nmol/L and 7.9% at 26.9 nmol/L. For DHT between run imprecision was 11.3% at a concentration of 1.3 nmol/L and 9.1% at 5.3 nmol/L. For E2 between run imprecision was 14.5% at a concentration of 73 pmol/L and 9.9% at 279 pmol/L. LH was assayed using a 2 step non-competitive chemiluminometric immunoassay (Abbott Architect, Abbott Diagnostics, Australia) with between run imprecision of 5.6% at 4.8 IU/L. SHBG was assayed using a solid phase, two-site enzyme immunometric assay with chemiluminescent substrate (Immulite 2000XPi, Siemens Healthcare) with between run imprecision of 3.4% at 39.4 nmol/L. Free T was calculated using empirical formulae which provides closer concordance with measured free T compared with calculations based on equilibrium binding equations [8] .
Statistical analyses
Descriptive statistics are presented as mean (SD). Linear regression models were used to examine the relationships between age, body mass index (BMI) (Tables 2 and 3 ). Non-linearity in relationships was investigated using both the square and log transform of quantitative risk factors. To identify the important and independent correlates of each hormone variable we used a forwards stepwise selection procedure using p<0.01 as the criterion for selection. The final fitted multivariable model from this procedure is presented (Table 4 
Results
Characteristics of the study population
There were 2,143 men who participated in the 1994/95 survey, who had provided blood samples for analysis. After excluding men reporting use of testosterone or hormonal therapy, or with a history of prostate cancer or orchidectomy n=48) and restricting the analysis to men with complete data for key variables, there were 1,920 men in this analysis. The mean (±SD) age was 50.3±17.0 years. Of these men, 43% had never smoked, 18.6% had hypertension, 3.1% were on lipid lowering therapy, 6.1% had diabetes, 2.9% had chronic pulmonary disease, 0.2% chronic renal disease and 16.8% had a history of CVD at the time of blood sampling. The age distribution of these men and the mean and SD of BMI, T, calculated free T, DHT, E2, SHBG and LH overall and for each age decade are shown in Table 1 . There was an even distribution of men across decades of age except for fewer men aged 80 years and above. The overall mean for BMI was 26.5 kg/m 2 and was highest in 50-69 year old men.
Total and calculated free T levels were lower in older compared to younger men, while SHBG and LH levels were higher in older men. 
Age-adjusted associations of hormones with smoking and obesity
All hormone variables were significantly positively associated with current smoking after adjustment for age. Total T, calculated free T, DHT, SHBG and LH were significantly (p<0.001) negatively associated with BMI, waist-hip-ratio and waist circumference and the strength of the association (effect size per SD change in obesity measure) was very similar for BMI, waist-hip-ratio and waist circumference (data not shown). E2 had a significant positive relationship with BMI (p=0.004) and non-significant relationships with waist-hipratio (p=0.481) and waist circumference (p=0.203). Thus in further analyses all associations with clinical and metabolic variables were adjusted for age, smoking and BMI.
Age, smoking and BMI-adjusted associations of hormones with clinical and metabolic factors
After adjustment for age, smoking and BMI, total T was positively associated with HDL, haemoglobin and adiponectin, and negatively associated with lipid lowering medication, hypertension, systolic BP, glucose, insulin, triglycerides, CRP and ALT (see Table 2 ).
Associations of calculated free T and DHT were similar to those found with total T, except that neither was associated with ALT, DHT was not associated with lipid lowering medication, DHT was lower in men with diabetes (p=0.012) and cholesterol was marginally positively associated with calculated free T (p=0.021). Associations of SHBG were also similar to those found with total T except that SHBG was not associated with lipid medications and haemoglobin, and was negatively associated with diastolic as well as systolic BP and hypertension. Of note, total and calculated free T, DHT and E2 were positively associated with HDL and haemoglobin and negatively associated with insulin, triglycerides and CRP. LH was negatively associated with haemoglobin (p=0.023) but was not associated with any other variable. Total and calculated free T, DHT and SHBG were strongly (p<0.001) negatively associated with the metabolic syndrome score whereas E2 was marginally associated with metabolic syndrome (p=0.039).
TABLE 2
Associations after additional adjustment for SHBG
Several associations with total and calculated free T, DHT and E2 were attenuated after further adjustment for SHBG (Table 3) . Total and calculated free T remained negatively associated with lipid medications, glucose and CRP, and positively associated with HDL and haemoglobin (p<0.05). DHT remained negatively associated with diabetes, glucose and CRP and positively associated with haemoglobin. E2 remained negatively associated with CRP and positively associated with haemoglobin. Alcohol consumption became more strongly associated with total and calculated free T, and cholesterol and creatinine more strongly associated with total and calculated free T and DHT after adjustment for SHBG. After adjustment for SHBG, the metabolic syndrome score remained negatively associated with total T (p=0.027) and calculated free T (p=0.027) but was not associated with DHT or E2. 
Multivariable models
The final multivariable models from the forward stepwise selection procedure are shown in Table 4 . Variables in these models are necessarily significant and independent determinants of the hormone variable but the variables not selected may still be related to hormone level (see Tables 2 and 3 ) with their capacity already conveyed through one or more of the selected variables with which they are correlated. The significant independent determinants of SHBG were age, smoking, chronic renal disease, HDL, and adiponectin (higher SHBG) and BMI, alcohol, insulin, triglycerides, CRP, creatinine (lower SHBG). The significant independent determinants of total and calculated free T were SHBG, alcohol consumption, creatinine and haemoglobin (higher T) and age, BMI, lipid medication and CRP (lower). The independent determinants of DHT were SHBG and haemoglobin (higher DHT) and age, BMI and glucose (lower). Age, BMI, SHBG and haemoglobin were independent determinants of E2, with the difference that higher BMI was associated with higher E2.
TABLE 4
Discussion
Higher total T was independently associated with younger age, reduced adiposity, alcohol consumption, absence of lipid lowering medication, haemoglobin and lower CRP. There were comparable associations of DHT with several of these factors, but DHT was independently associated with lower glucose and not with alcohol or lipid medication. E2 levels were associated with age and haemoglobin, with a positive association with BMI.
Age was an independent determinant of both total and calculated free T levels, even allowing for SHBG. Medical comorbidities including diabetes and CVD were not independently reported similar reference intervals for T in healthy young and elderly men, consistent with the presence of ill-health underlying lower total T in elderly men [7] . In our cohort of men spanning a wider age range with co-existing medical comorbidities, increasing age was an independent determinant of lower total and free T levels, which were not lower in the presence of diabetes, pulmonary, renal or cardiovascular disease. We did not assess selfreported very good or excellent health in our study; therefore it remains possible some men without specific medical conditions might have been unwell with low levels of T. However, our results are consistent with findings in older men which support the concept that lower T levels in men across a span of ages are at least in part an age-associated phenomenon [20] .
Our results are consistent with previous studies which identified central adiposity assessed via BMI, waist circumference or fat mass as being closely associated with lower total T levels in men [21, 22] . We found that while DHT and E2 levels appeared to be stable across decades of age, in the final multivariable model age was an independent determinant of these hormones. While age-associated changes in calculated free DHT have been reported to parallel trends seen with calculated free T, the calculation of free DHT based on immunoassay for total DHT and SHBG has not been well validated [23] . Previously Feldman et al measured DHT by radioimmunoassay in the Massachusetts Male Ageing Study [2] . In 25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54  55  56  57  58  59  60 F o r P e e r R e v i e w 13 that study the cross-sectional analysis of 1,709 men aged 40-70 years showed no association of DHT with age, but the longitudinal analysis found higher DHT levels in the subset of 1,156 men followed after 7-10 years. Our results contrast with previous reports of negative associations between E2 and age in cross-sectional studies using immunoassays [18, 19] , but are consistent with the cross-sectional analysis from the Framingham Heart Study of 1,461 men aged from 30 to 80+ years [24] . In that study E2 was measured by LC-MS, and was positively associated with age. Therefore, when measured accurately using LC-MS, E2 is positively associated with age and BMI, and does not share the associations of T with metabolic factors. Longitudinal studies are required to clarify the evolution of hormone profiles with ageing.
Strengths of our study are the large size of the cohort, its inclusion of men spanning younger, middle and older ages, extensive phenotyping and availability of physical, metabolic and laboratory variables for the analyses. We assayed total T, DHT and E2 using LC-MS which provides a more accurate measurement compared to immunoassays. We explored associations of total and calculated free T, DHT and E2 with variables of interest after systematically adjusting for age, smoking, BMI and SHBG, and then using a multivariable model to identify factors independently associated with hormone levels. Thus we were able to compare distributions of T, DHT and E2 across age groups from young to old, and contrast the associations of each hormone with a range of health-related factors in a community-based cohort of men spanning young to older ages. We acknowledge several limitations of this study. This is an observational study and we performed a cross-sectional analysis thus we cannot infer causation. While WADLS possesses accuracy comparable to adjudication of medical records [25] , individuals who did not require hospitalisation might not be identified by this means and reliance on data linkage remains a limitation. The men were community- However, the same may not be true for proteins such as SHBG and LH. We did not have serial blood samples to assess longitudinal changes in hormones levels, instead we used a single blood sample albeit collected early in the morning to minimise the effect of circadian variation on hormone levels which may be preserved in healthy older men [29] . Additionally the Busselton cohort is almost entirely Caucasian in ethnicity thus care must be taken before extrapolating our findings to other populations.
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